109 related articles for article (PubMed ID: 32100221)
21. A Look at the Other Side: High-Risk Lesions and Occult Contralateral Malignancy in Symmetry Procedures for Patients Undergoing Oncoplastic Breast-Conserving Surgery.
Jackson KM; Millen JC; Orozco JIJ; Stern SL; Fancher CE; Grumley JG
Ann Surg Oncol; 2023 Oct; 30(10):6159-6166. PubMed ID: 37535266
[TBL] [Abstract][Full Text] [Related]
22. Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
Punglia RS; Jiang W; Lipsitz SR; Hughes ME; Schnitt SJ; Hassett MJ; Nekhlyudov L; Achacoso N; Edge S; Javid SH; Niland JC; Theriault RL; Wong YN; Habel LA
Breast Cancer Res Treat; 2018 Feb; 167(3):751-759. PubMed ID: 29079937
[TBL] [Abstract][Full Text] [Related]
23. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
[TBL] [Abstract][Full Text] [Related]
24. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
[TBL] [Abstract][Full Text] [Related]
25. External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.
Jung JJ; Kang E; Kim EK; Kim SM; Jang M; La Yun B; Park SY; Shin HC
Breast Cancer Res Treat; 2020 Sep; 183(2):373-380. PubMed ID: 32647937
[TBL] [Abstract][Full Text] [Related]
26. Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.
Cronin PA; Olcese C; Patil S; Morrow M; Van Zee KJ
Ann Surg Oncol; 2016 Sep; 23(9):2816-24. PubMed ID: 27198513
[TBL] [Abstract][Full Text] [Related]
27. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.
Rakovitch E; Nofech-Mozes S; Hanna W; Baehner FL; Saskin R; Butler SM; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Robertson SJ; Slodkowska E; Fong C; Anderson JM; Jamshidian F; Miller DP; Cherbavaz DB; Shak S; Paszat L
Breast Cancer Res Treat; 2015 Jul; 152(2):389-98. PubMed ID: 26119102
[TBL] [Abstract][Full Text] [Related]
28. Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.
Mamtani A; Nakhlis F; Downs-Canner S; Zabor EC; Morrow M; King TA; Van Zee KJ
Ann Surg Oncol; 2019 Dec; 26(13):4264-4271. PubMed ID: 31440931
[TBL] [Abstract][Full Text] [Related]
29. Does intraductal breast cancer spread in a segmental distribution? An analysis of residual tumour burden following segmental mastectomy using tumour bed biopsies.
Jenkinson AD; Al-Mufti RA; Mohsen Y; Berry MJ; Wells C; Carpenter R
Eur J Surg Oncol; 2001 Feb; 27(1):21-5. PubMed ID: 11237487
[TBL] [Abstract][Full Text] [Related]
30. Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center.
Rosenberger LH; Mamtani A; Fuzesi S; Stempel M; Eaton A; Morrow M; Gemignani ML
Ann Surg Oncol; 2016 Oct; 23(10):3239-46. PubMed ID: 27411549
[TBL] [Abstract][Full Text] [Related]
31. Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Baehner FL; Miller DP; Fong C; Gu S; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Slodkowska E; Anderson JM; Cherbavaz DB; Shak S; Paszat L
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053207
[TBL] [Abstract][Full Text] [Related]
32. Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.
Sprague BL; Vacek PM; Herschorn SD; James TA; Geller BM; Trentham-Dietz A; Stein JL; Weaver DL
Breast Cancer Res Treat; 2019 Feb; 174(1):227-235. PubMed ID: 30448897
[TBL] [Abstract][Full Text] [Related]
33. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
34. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis.
Warren JL; Weaver DL; Bocklage T; Key CR; Platz CE; Cronin KA; Ballard-Barbash R; Willey SC; Harlan LC
Cancer; 2005 Nov; 104(9):1840-8. PubMed ID: 16136599
[TBL] [Abstract][Full Text] [Related]
35. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
36. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
[TBL] [Abstract][Full Text] [Related]
37. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
[TBL] [Abstract][Full Text] [Related]
38. Impact of core biopsy on the management of screen-detected ductal carcinoma in situ of the breast.
Cheng MS; Fox J; Hart SA
ANZ J Surg; 2003 Jun; 73(6):404-6. PubMed ID: 12801338
[TBL] [Abstract][Full Text] [Related]
39. Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.
Solin LJ; Fourquet A; McCormick B; Haffty B; Recht A; Schultz DJ; Barrett W; Fowble BL; Kuske R; Taylor M
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):3-9. PubMed ID: 8083125
[TBL] [Abstract][Full Text] [Related]
40. Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm.
Hamilton SN; Nichol A; Wai E; Gondara L; Velásquez García HA; Speers C; Diocee R; Truong P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):381-388. PubMed ID: 30253237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
